Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication

Journal of Medicinal Chemistry

Volumn 53, Issue 8, 2010, Pages 3117-3126

  Stankiewicz Drogoń, Anna ^a   Dörner, Bernd ^b   Erker, Thomas ^b   Boguszewska Chachulska, Anna M ^c,d  

^a INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

^b UNIVERSITY OF VIENNA   (Austria)

^c Genomed   (Poland)

^d WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIDONE DERIVATIVE; ANTIVIRUS AGENT; AROMATIC AMINE; CARBOXYLIC ACID DERIVATIVE; ENZYME INHIBITOR; NS3 HELICASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INHIBITION KINETICS; NONHUMAN; REACTION ANALYSIS; REPLICON; VIRUS REPLICATION;

ACRIDONES; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HUMANS; MODELS, MOLECULAR; MUTATION; REPLICON; RNA HELICASES; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77951106714     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901741p     Document Type: Article

References (33)

1. Hayashi, N.; Takehara, T. Antiviral therapy for chronic hepatitis C: past, present, and future J. Gastroenterol. 2006, 41, 17-27
2. Reesink, H. W.; Zeuzem, S.; Weegink, C. J.; Forestier, N.; Van Vliet, A.; Van De Wetering De Rooij, J.; McNair, L.; Purdy, S.; Kauffman, R.; Alam, J.; Jansen, P. L. M. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 2006, 131, 997-1002
3. Manns, M.; Muir, A.; Adda, N.; et al. Telaprevir in hepatitis C genotype-1-infected patients with prior non-response, viral breakthrough or relapse to peginterferon-alfa-2a/b and ribavirin therapy: SVR results of the PROVE3 study. In 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009), Copenhagen, 2009.
4. Kwo, P.; Lawitz, E.; McCone, J.; Schiff, E.; Vierling, J.; Pound, D.; Davis, M.; Galati, J.; Gordon, S.; Ravendhran, N.; Rossaro, L.; Anderson, F.; Jacobson, I.; Rubin, R.; Koury, K.; Brass, C.; Chaudhri, E.; Albrecht, J. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus pegintron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. In 44th Annual Meeting of the European Association for the Study of the Liver (EASL), Copenhagen, 2009.
5. Thompson, A.; Patel, K.; Tillman, H.; McHutchison, J. G. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges J. Hepatol. 2009, 50, 184-194
6. Frick, D. N. The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target Curr. Issues Mol. Biol. 2007, 9, 1-20
7. Lam, A. M.; Frick, D. N. Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase J. Virol. 2006, 80, 404-411
8. Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron, P. R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding Structure 1998, 6, 89-100
9. Lam, A. M.; Rypma, R. S.; Frick, D. N. Enhanced nucleic acid binding to ATP-bound hepatitis C virus NS3 helicase at low pH activates RNA unwinding Nucleic Acids Res. 2004, 32, 4060-4070
10. Gozdek, A.; Zhukov, I.; Polkowska, A.; Poznanski, J.; Stankiewicz-Drogon, A.; Pawlowicz, J. M.; Zagorski-Ostoja, W.; Borowski, P.; Boguszewska- Chachulska, A. NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. M Antimicrob. Agents Chemother. 2008, 52, 393-401
11. Krawczyk, M.; Wasowska-Lukawska, M.; Oszczapowicz, I.; Boguszewska-Chachulska, A. M. Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds Biol. Chem. 2009, 390, 351-360
12. Stankiewicz-Drogon, A.; Palchykovska, L. G.; Kostina, V. G.; Alexeeva, I. V.; Shved, A. D.; Boguszewska-Chachulska, A. M. New acridone-4-carboxylic acid derivatives as potential inhibitors of Hepatitis C virus infection Bioorg. Med. Chem. 2008, 16, 8846-8852
13. Manfroni, G.; Paeshuyse, J.; Massari, S.; Zanoli, S.; Gatto, B.; Maga, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Neyts, J. Inhibition of subgenomic hepatitis C virus RNA replication by acridone derivatives: identification of an NS3 helicase inhibitor J. Med. Chem. 2009, 52, 3354-3365
14. Sharp, M. J.; Mader, C. J.; Strachan, C.; Synthesis of acridine derivative as multidrug-resistant inhibitors. (Glaxo Group Ltd., UK). PCT Int. Appl., 1998.
15. Dörner, B.; Kuntner, C.; Bankstahl, J. P.; Bankstahl, M.; Stanek, J.; Wanek, T.; Stundner, G.; Mairinger, S.; Löscher, W.; Müller, M.; Langer, O.; Erker, T. Synthesis and Small-Animal Positron Emission Tomography Evaluation of [11C]-Elacridar As a Radiotracer to Assess the Distribution of P-Glycoprotein at the Blood-Brain Barrier J. Med. Chem. 2009, 52, 6073-6082
16. Boguszewska-Chachulska, A. M.; Krawczyk, M.; Stankiewicz, A.; Gozdek, A.; Haenni, A. L.; Strokovskaya, L. Direct fluorometric measurement of hepatitis C virus helicase activity FEBS Lett. 2004, 567, 253-258
17. Klumpp, K.; Leveque, V.; Le Pogam, S.; Ma, H.; Jiang, W. R.; Kang, H.; Granycome, C.; Singer, M.; Laxton, C.; Hang, J. Q.; Sarma, K.; Smith, D. B.; Heindl, D.; Hobbs, C. J.; Merrett, J. H.; Symons, J.; Cammack, N.; Martin, J. A.; Devos, R.; Najera, I. The novel nucleoside analog R1479 (4′- azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture J. Biol. Chem. 2006, 281, 3793-3799
18. Prichard, M. N.; Shipman, C., Jr. A three-dimensional model to analyze drug-drug interactions Antiviral Res. 1990, 14, 181-205
19. Bastow, K. F. New acridone inhibitors of human herpes virus replication Curr. Drug Targets Infect. Disord. 2004, 4, 323-330
20. Bernardino, A. M.; Castro, H. C.; Frugulhetti, I. C.; Loureiro, N. I.; Azevedo, A. R.; Pinheiro, L. C.; Souza, T. M.; Giongo, V.; Passamani, F.; Magalhaes, U. O.; Albuquerque, M. G.; Cabral, L. M.; Rodrigues, C. R. SAR of a series of anti-HSV-1 acridone derivatives, and a rational acridone-based design of a new anti-HSV-1 3H-benzo[b]pyrazolo[3,4- h ]-1,6-naphthyridine series Bioorg. Med. Chem. 2008, 16, 313-321
21. Adams, A. Crystal structures of acridines complexed with nucleic acids Curr. Med. Chem. 2002, 9, 1667-1675
22. Tuteja, N.; Phan, T. N.; Tuteja, R.; Ochem, A.; Falaschi, A. Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents Biochem. Biophys. Res. Commun. 1997, 236, 636-640
23. Tackett, A. J.; Wei, L.; Cameron, C. E.; Raney, K. D. Unwinding of nucleic acids by HCV NS3 helicase is sensitive to the structure of the duplex Nucleic Acids Res. 2001, 29, 565-572
24. Goodell, J. R.; Madhok, A. A.; Hiasa, H.; Ferguson, D. M. Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity Bioorg. Med. Chem. 2006, 14, 5467-5480
25. Piestrzeniewicz, M. K.; Wilmanska, D.; Studzian, K.; Szemraj, J.; Czyz, M.; Denny, W. A.; Gniazdowski, M. Inhibition of RNA synthesis in vitro by acridines - relation between structure and activity Z. Naturforsch., C: J. Biosci. 1998, 53, 359-368
26. Dziegielewski, J.; Slusarski, B.; Konitz, A.; Skladanowski, A.; Konopa, J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity Biochem. Pharmacol. 2002, 63, 1653-1662
27. Glenn, J. S. Small molecule approaches to NS4B and other novel non-structural protein targets. In HCV Drug Discovery, San Diego, CA, 2009.
28. Coelmont, L.; Paeshuyse, J.; Windisch, M. P.; De Clercq, E.; Bartenschlager, R.; Neyts, J. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine Antimicrob. Agents Chemother. 2006, 50, 3444-3446
29. Watterson, S. H.; Chen, P.; Zhao, Y.; Gu, H. H.; Dhar, T. G.; Xiao, Z.; Ballentine, S. K.; Shen, Z.; Fleener, C. A.; Rouleau, K. A.; Obermeier, M.; Yang, Z.; McIntyre, K. W.; Shuster, D. J.; Witmer, M.; Dambach, D.; Chao, S.; Mathur, A.; Chen, B. C.; Barrish, J. C.; Robl, J. A.; Townsend, R.; Iwanowicz, E. J. Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: discovery and SAR leading to the identification of N -(2-(6-(4-ethylpiperazin- 1-yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3- carboxamide (BMS-566419) J. Med. Chem. 2007, 50, 3730-3742
30. Zhou, S.; Liu, R.; Baroudy, B. M.; Malcolm, B. A.; Reyes, G. R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA Virology 2003, 310, 333-342
31. Vance, J.; Bastow, K. F. Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone Biochem. Pharmacol. 1999, 58, 703-708
32. Boguszewska-Chachulska, A. M.; Krawczyk, M.; Najda, A.; Kopanska, K.; Stankiewicz-Drogon, A.; Zagorski-Ostoja, W.; Bretner, M. Searching for a new anti-HCV therapy: synthesis and properties of tropolone derivatives Biochem. Biophys. Res. Commun. 2006, 341, 641-647
33. Vrolijk, J. M.; Kaul, A.; Hansen, B. E.; Lohmann, V.; Haagmans, B. L.; Schalm, S. W.; Bartenschlager, R. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C J. Virol. Methods 2003, 110, 201-209